FDA Adverse Event Other Summary report: N

BIOPATCH 3151

MDR report key: 1637204 · Received March 19, 2010

Report

Report Number
2648988-2010-00019
Event Type
Other
Date Received
March 19, 2010
Date of Event
April 4, 2008
Report Date
March 19, 2010
Manufacturer
INTEGRA NEUROSCIENCES PR
Product Code
FRO
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NJ, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

A RECENT INTERNAL AUDIT OF INVESTIGATED COMPLAINTS THAT HAVE BEEN RECEIVED DURING THE PAST TWO YRS DETERMINED THAT THIS EVENT, THAT FULFILLS INTEGRA LIFESCIENCES CORP'S REPORTING REQUIREMENTS, WAS NOT REPORTED PREVIOUSLY TO THE FDA. NO LOT NUMBER WAS PROVIDED AND NO PRODUCT COMPLAINT SAMPLE WAS AVAILABLE FOR RETURN FOR EXAMINATION. AS A RESULT, THE DEVICE HISTORY RECORD COULD NOT BE REVIEWED. INTEGRA'S INVESTIGATION WAS UNABLE TO CONFIRM THE COMPLAINT. NO CORRECTIVE ACTION IS CONSIDERED TO BE NECESSARY. THE COMPLAINT RATE FOR THIS PRODUCT FAMILY IS 0.0005%. INTEGRA CONSIDERS THIS COMPLAINT INVESTIGATION CLOSED. FUTURE INCIDENTS OF THIS NATURE WILL BE DOCUMENTED FOR RECURRENCE AND TRENDING PURPOSES.

Description of Event or Problem · 1

THE REPORTER STATED THAT A BIOPATCH WAS USED AS A DRESSING ON THE INSERTION SITE OF A SUBCLAVIAN TRIPLE LUMEN CATHETER THAT WAS IN PLACE TO ADMINISTER NORMAL SALINE AND INTRAVENOUS MEDICATION. THE CATHETER WAS IN PLACE FOR FIVE DAYS. WHEN THE BIOPATCH DRESSING WAS CHANGED AFTER FIVE DAYS, THERE WAS NO ABNORMALITY NOTED. AFTER A FURTHER FIVE DAYS, PUS AND REDNESS WERE OBSERVED AT THE CATHETER INSERTION SITE. ON REMOVAL OF THE CATHETER, THE CATHETER TIP WAS SENT FOR BACTERIAL CULTURE. THE RESULTS OF THE CULTURE WERE NEGATIVE. A NEW SUBCLAVIAN LINE WAS INSERTED AT A SITE ON THE PT'S OPPOSITE SIDE. NO FURTHER TREATMENT WAS PROVIDED. BIOPATCH WAS USED AGAIN ON THIS PT WITHOUT FURTHER INCIDENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 BIOPATCH 3151 ANTIMICROBIAL PRODUCTS FRO INTEGRA NEUROSCIENCES PR

Patients

Seq Age Sex Outcome Treatment
1 Other